Our technology platform
Our novel drug discovery platform incorporates and integrates the best our vast biotechnical expertise offers, optimized to find novel solutions to unmet vision threatening diseases. Our multidisciplinary team is highly focused on finding the best solutions to the most severe ocular disease challenges faced by patients today, combining expertise in medicinal chemistry, genetic engineering, pharmacokinetics, and regulatory affairs to deliver innovative and effective therapeutic solutions. Theialife has a unique approach to ocular disease targeting & finding pathways for solutions in a sustainable way.
COLLABORATIONS
Theialife is open to collaborations with biotechnology, pharmaceutical, and other strategic partners to discover, develop and commercialize innovative treatments in the fields of ophthalmology & ocular diseases. We welcome opportunities to partner through in- and out-licensure, co-development, region-specific agreements, joint ventures, and other collaborations.
Theialife is committed to developing first- and/or best-in-class therapeutics for vision-threatening diseases – to help patients see better & have a better quality of life.
We actively seek to expand our pipeline of promising investigational therapies. Our company is actively seeking our next potential partner for licensing and commercialization opportunities for its portfolio assets as well as investment opportunities.
INVESTMENT OPPORTUNITIES
Theialife is open to collaborations with biotechnology, pharmaceutical, and other strategic partners to discover, develop and commercialize innovative treatments in the fields of ophthalmology & ocular diseases. We welcome opportunities to partner through in- and out-licensure, co-development, region-specific agreements, joint ventures, and other collaborations.
Theialife is committed to developing first- and/or best-in-class therapeutics for vision-threatening diseases – to help patients see better & have a better quality of life.
Sight-threatening diseases constitute a large and growing market opportunity. With changing population demographics, the incidence of many ocular diseases, especially Myopia is increasing. New, innovative & novel therapies are required to treat this silent epidemic. If you are interested in joining in this journey to protect the vision of children all over the world, please feel free to get in touch.
STRATEGIC PARTNERSHIP
Global partnerships provide the opportunity for us to continue to build an innovative portfolio of advanced therapeutics in ophthalmic diseases. We also offer an entry point for novel treatments development for the worldwide market. With extensive experience in global product development (drugs) our team can help maximize the value of innovative technology towards the shared goal of benefiting patients with vision-impaired diseases.
We can develop novel cell lines that produce high-tier therapeutics for ocular diseases through genetic engineering and large scale screening. By understanding disease mechanisms better, novel cell lines can be used to manufacture biologic drugs, which increases accessibility by being more efficient and cost-effective.
Analytical development
Novel drug design
We have the capability to synthesize multiple drug molecules in parallel to evaluate their functions and create new compounds & complex molecular structures. This helps translate our novel drug design & crystallize our ideas.
Our expert scientists understand how to subject genetically engineered bacterial cells to produce metabolites. Further, optimizing growth conditions to enhance productivity of various drug molecules.
Metabolic and genetic engineering
